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Management of membranoproliferative glomerulonephritis: titis C has been increasingly implicated as a cause of
Evidence-based recommendations. Idiopathic membranoproli- MPGN over the last five years [2–4], and the association
ferative glomerulonephritis (MPGN) is one of the least com- of MPGN with HIV disease has also been described [5].mon types of GN. This article critically evaluates the literature
Given the rising prevalence of these diseases, appro-and generates evidence-based recommendations for the man-
priate serology must be obtained in patients presentingagement of idiopathic MPGN. For all age groups, for idiopathic
MPGN with normal renal function and asymptomatic nonne- with apparently idiopathic MPGN. Because there are a
phrotic range proteinuria, no specific therapy is necessary number of other noninfectious secondary causes with
(grades B and C). Close follow-up every three to four months,
different treatment regimens and outcomes [2–8], it iswith specific attention to renal function, proteinuria, and blood
important to conduct a thorough and focused search forpressure control, is recommended. In children with MPGN and
nephrotic syndrome and/or impaired renal function, a trial of secondary causes.
steroids is warranted (grade A). The best data suggest high- The pathogenesis of MPGN has been well studied,
dose, alternate-day steroids for a period of 6 to 12 months (40 and improved understanding has led to the search for
mg/m2 on alternate days). If no benefit is seen, discontinuation
agents that will modify the intense cellular proliferationwith close follow-up and attention to conservative treatment
and immune deposition that occurs. Immune-modulating(that is, blood pressure control, use of agents to reduce protein-
uria, and correction of metabolic abnormalities) is recom- therapy and therapy that interferes with the biological
mended. In adults with MPGN, impaired renal function, and/ processes (for example, platelet activation) proposed to
or nephrotic-range proteinuria, a trial of aspirin (325 mg daily), be central in the pathogenesis of the MPGN lesion havedipyridamole (75 to 100 mg tid), or a combination of the two
been evaluated in human trials [2].for 12 months is reasonable (grade B). Again, if no benefits are
seen, the treatment should be stopped. Attention to factors The focus of this article is to review the clinical studies
known to delay the progression of renal decline and close follow- or trials in treatment of patients with idiopathic MPGN
up should be part of the treatment plan (grades B and C). and to critically evaluate the quality of that data in order
to make evidence-based recommendations for treat-
ment.
Among all of the glomerulonephritides, membrano-
proliferative glomerulonephritis (MPGN) is one of the
least common. It primarily affects children and young METHODS
adults, with the mean age of onset ranging between 8 Human clinical trials, including adults and children,
and 30 years. Conventionally, it has been classified as were reviewed from the English language literature from
idiopathic or secondary, with idiopathic MPGN further 1927 to 1997. Twenty-one studies were selected for re-
subdivided into types I through III based on morphologi- view after an extensive MEDLINE search using the key
cal pattern. This disease has had many different names words mesangiocapillary, membranoproliferative and
over the years, including lobular, hypocomplementemic, lobular GN, clinical trials, and therapies. The articles
and mesangiocapillary GN. There has been a decline in selected include over 1100 patients with MPGN (all sub-
the incidence of primary MPGN over the two decades [1]. types and age groups).
The diagnosis of MPGN requires the exclusion of all Studies were evaluated based on the levels of evidence,
secondary causes such as hepatitis B or C, HIV, other graded 1 through 6 using the study design, size, power,
infections, or collagen vascular disease (grade B). Hepa- and end points as criteria for evaluation. Recommenda-
tions were then graded based on the level of evidence
of the supporting studies. Grades A through D are basedKey words: idiopathic MPGN, secondary MPGN, hepatitis C, ne-
phrotic syndrome, interstitial disease. on the number, type, and strength of studies available
[9–12]. 1999 by the International Society of Nephrology
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Table 1. Immune modulating therapy: Steroids, cyclophosphamide
Level of
evidence Author [Ref] Design N(Rx/C) Rx (dose) Duration Results/comments
1 Tarshish [18] RCT 8(47/33) Prednisone (40 mg/m2) vs. 130 months (mean) Children only,
placebo predominantly MPGN I
stable renal function 61%
(Rx) vs. 12% (C)
1 Cattran [20] RCT 59(27/ Cyclophosphamide, 18 months No difference found, mixed
32) dypridamole and ASA MPGN I . II
vs. no therapy
3 Strife [26] UTC 17(16/1) Prednisone 2 mg/kg alt day 2 years MPGN III only. Nephrotic
range did worse, 3/16
developed RF
3 Davis [27] CT 27(19/8) Prednisone and — No effect
immunosuppressives
(NS)
3 Orlowski [24] UCT 50 P/Aza/CP/chlorambucil in 79 months 10 year follow-up, reduce
combinations urine protein with triple
drug therapy
3 Ford [23] UCT 19 Oral/i.v. Pred (2 mg/kg) 1 8–10 week initial Children; 6.5 year follow-up,
ACEI therapy, then 3 early therapy, shorter
2–3 years course, reduce glomerular
tapered dose proliferation
3 Faedda [28] UCT 19 i.v./p.o. Cyclo and P (in 10 months 15/19 clinical remission, 7
different combinations) year follow-up
3 Bergstein [29] UCT 16 6 3 alt day i.v. MP, then Mean duration 37 Mean follow-up 5 57 months,
p.o. prednisone alt day months therapy children, type I, all
parameters of renal
function, proteinuria
improved after 3 months.
Repeat kidney bx
improved acute but worse
chronic changes
4 Habib [25] UCT 97(28/ Prednisone vs. placebo — No effect
69)
4 McEnery [22] CS 6 Prednisone alt day 14 years Type II, children, serial renal
bx: reduce proliferative
changes 37% remission,
89% 10 year renal survival
4 Arslap [30] CS 96 Prednisone or Cyclo 6 i.v. 10 year follow-up If Pred failed, then Cyclo 6
MP i.v. MP given with 25 and
50% remission; 10 year
survival 61–81%
4 Emre [31] CS 15 i.v. Pulse MP 30 mg/kg alt Mean 27 months 9/15 responsive, children
days 3 9–15 days; then (6–84) significant reduction
oral Pred 1 mg/kg 3 1 proteinuria
month, tapered off 3 1
month
4 Takeda [32] CS 18 i.v. MP, Dp and oral Pred Median 6 years Children, 94% renal survival
(3–15.5 years) at 4–10 years post-clinical
onset; variable group: mild
urinary abnormalities
(12/18), heavy proteinuria
(3/18), mild renal
insufficiency (3/18)
4 Itaka [33] CS 41 3 therapies: low dose Pred, 8 years Children, identified by school
low dose followed by screening 32 Type 1, 2
high dose alt day Pred, Type II, 7 type III; best
high dose alt day Pred outcomes 5 those with
alone high dose alt day Pred;
1/41 ESRD? utility of early
screening and therapy
Abbreviations are: RCT, randomized control trial; CT, controlled trial; UCT, uncontrolled trial; CS, case series; DS, descriptive study; Rx, treatment group;
C, control group; fn, function; NS, nonsignificant; N, number in study; P, prednisone; MP, methylprednisolone; i.v., intravenous; p.o., oral; alt day, alternative
day; ASA, asprin; Dp, dipyridamole; Chlor, Chlorambucil; CP, cyclophosphamide; sign diff, significant difference; AZA, azathioprine.
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Table 2. Non-immune modulating therapy: ASA, dipyridamole
Level of
evidence Author [Reference] Design N (Rx/C) Rx (dose) Duration Results/comments
1 Donadio [19] RCT 40 (21/19) Dipyridamole (275 mg/day 12 months t1⁄2 platelets and renal function. Rapid
and ASA (975 mg/day vs. decline in control group, sign diff
placebo at 3–5 year, NS 10 year renal fn
1 Zimmerman [17] RCT, 18 (8/10) Warfarin (target INR 1.5–2) 12 months Protein restriction and HTN control
cross dipyridamole (75–100 mg (2 year study) standardized. Significant reduction
over qid) vs. placebo in proteinuria, ns difference in re-
nal function
1 Zauner [21] RCT 18 (9/9) ASA (500 mg/day) and di- 36 months Significant reduction in proteinuria
pyridamole (75 mg/day) Rx group (1 g Uprotein vs. 8 g Uprotein
(both got protein restric- control group P , 0.5)
tion and HTN control)
Abbreviations are in Table 1.
Table 3. Natural history studies
Level of
evidence Author reference Design N Treatment Duration Rx/Fup Results/comments
3 Schmitt [6] DS 220 — 59 month mean follow-up 65% 10 year survival
3 Confalonerri [7] DS 294 — 60 month mean follow-up 60% 10 year survival
MPGN II, progressive disease 5 ne-
phrotic syndrome and TI changes; C3
4 Bennett [8] DS 27 — — ? predictive
Adults and children, Types I and II/
4 Cameron [9] DS 104 — 8 years mean follow-up nephrotic
Recommendations suppressive agents. They are varied in study design, dura-
tion of follow-up, and inclusion of patients with differentRecommendation 1. Treatment in adults and children
types of MPGN. Furthermore, the studies vary in defini-with idiopathic MPGN is reserved for those patients with
tion of successful treatment (reduction in proteinuria,proteinuria of greater than 3 g/day, interstitial disease
renal survival, and regression of lesions on biopsy), oftenon biopsy, or impaired renal function (grades B and C).
making comparisons difficult. However, specific therapyEvidence. The natural history of MPGN has been
can be recommended in certain instances (Figure 1).studied in a number of large European studies, which
Of the 13 treatment trials available in the literature,have shown a 60% 10-year renal survival for idiopathic
eight used steroids either alone or in combination withMPGN. The level 4 natural history studies of Schmitt et
other treatment. Regimens included alternate-day ste-al [6] and Confaloneiri et al [7], with over 500 patients
roids, intravenous boluses of steroids, and a combinationfollowed, confirmed earlier findings that the 10-year re-
of intravenous and oral therapy. Duration of treatmentnal survival of MPGN is approximately 60 to 65%. These
was variable, ranging from less than 6 months to overhistorical reviews describe a large number of patients
130 months. This review considered changes in renalfollowed in Italy, Germany, United Kingdom, and Aus-
function, as well as reduction in proteinuria as objectivetralia in an attempt to define adverse prognostic factors
and clinically meaningful end points.in patients with MPGN [13–16]. Nephrotic syndrome
Only five randomized clinical trials have been pub-(heavy proteinuria) and the presence of interstitial dis-
lished with sufficient power to determine the benefits ofease are the main adverse prognostic signs [14, 15].
therapy in this rare disease (level 1 data) [17–21]. TablesRecommendation 2. Children with idiopathic MPGN,
1, 2, and 3 provide an overview of the studies included,proteinuria (more than 3 g/day), or impaired renal func-
grouped according to type of therapy, and subgroupedtion may respond to high-dose steroid therapy, which
according to the level of evidence.should be maintained for 6 to 12 months (grade A).
One of these five trials exclusively studied childrenRecommendation 3. Adults with idiopathic MPGN,
and showed that prednisone (40 mg/m2 alternate days)proteinuria (more than 3 g/day), or impaired renal func-
when compared with placebo was of benefit in slowingtion should undergo a trial of therapy with dipyridamole
the change in glomerular filtration rate (GFR) over timeor aspirin (grade B).
and stabilizing renal function in children with MPGN.Evidence. Treatment studies have compared anti-
platelet agents, coumadin, steroids, and other immuno- Eighty children, predominantly with MPGN type 1, were
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Fig. 1. Algorithm for the treatment and follow-up of mesangial proliferative glomerulonephritis (MPGN).
enrolled in the study, with a mean duration of treatment Donadio et al’s randomized 40 patients to examine
the effect of dipyridamole and aspirin on renal outcomeof 130 months: 61% of the treatment group versus 12%
of the placebo group had stable renal function at the and the t1/2 of platelets. Both measures were improved
by the antiplatelet therapy compared with placebo [19].end of the study period (level 1 evidence) [18]. Other
less well-designed studies have corroborated the finding However, in the control group, the rate of renal deterio-
ration was quite rapid and has led to concerns about thethat steroids are useful in the treatment of MPGN in
children (level 3 to 4 evidence) [22–25]. representativeness of the control group. Zauner et al’s
1994 study of 18 people, also treated with aspirin (ASA)The other four randomized, controlled studies were
smaller, enrolled more heterogeneous groups of patients, and dipyridamole, compared therapy with no therapy
over a 36 month follow-up. Both groups received similarincluding both children and adults, and had different
end points (proteinuria, renal function measured using protein restriction and antihypertensive regimens. The
study demonstrated a clinically significant effect of re-variable techniques, etc.). These randomized controlled
trials are offered as level 1 and 2 evidence for the use duction in proteinuria in the treatment group, but no
change in GFR [21].of antiplatelet agents in adults.
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Another prospective study involved 18 patients over therapy. No study has addressed these particular issues
in an objective format.two study years (placebo and treatment), comparing war-
farin and dipyridamole against placebo. The active treat-
ment group showed reduced proteinuria but very little
SUMMARY
impact on GFR. An increased incidence of bleeding was
The recommendations offered here are based on thenoted in the treatment groups [17].
best level of evidence in an attempt to rationalize theCattran et al studied the effect of cyclophosphamide
current therapy for idiopathic MPGN. Steroid therapyand coumadin and dipyridamole therapy in patients with
has been proven effective for children but not for adults.MPGN in 59 patients. Therapy was continued for 18
This situation is similar to that previously existing inmonths. These investigators were unable to show a dif-
the focal segmental glomerulosclerosis (FSGS) literatureference between control and treatment groups after this
[30]. A number of unanswered general questions in thislength of time. They were also unable to define any
disease remain, which include the optimal proactivepredictors of renal decline, perhaps in part because all
management of steroid complications, the proper dosinghad nephrotic range proteinuria as part of the entry
and tapering of medications, and the projected durationcriteria to the study. The authors were careful to state
of the study that would be needed to revise the currentthat their study was able to address treatment issues
therapeutic recommendations.clearly in only patients with MPGN type I, and did not
A number of logistical problems are inherent in thehave sufficient power to offer any conclusions for those
study of a rare GN, especially one with a long naturalwith type II disease [20].
history. Despite this, patients and their physicians doThus, in 215 patients involved in robust randomized
require guidance, and the review of evidence is importantcontrolled trial (RCT) study designs (level 1 to 2 evi-
to guide practice and follow-up. These recommendationsdence), little benefit has been found in adults with any
attempt to address those needs. Future studies will needimmunosuppressive therapy, but the data do suggest a
to address shortcomings of previous data and will requirepossible benefit of antiplatelet therapy. Reduction of
collaborative efforts.proteinuria has been used as a surrogate measure of
success and may be an important clinical outcome in Reprint requests to Adeera Levin, M.D., St. Paul’s Hospital, 1081
Burrard Street, Room 6010 A Providence Wing, Vancouver, BC V6Zthis patient group. Rigorous studies comparing high-dose
1Y6, Canada.steroids (the effective regimen for children) with ASA
E-mail: alevin@stpaulshosp.bc.ca
and dipyridamole in high-risk adult patients have not
been performed.
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